Key takeaways
- Injectables are temperature-sensitive and route only to cold-chain-qualified pharmacies.
- Oral formats remove the cold chain constraint, which widens the states you can reliably serve.
- Needle aversion is a real and underestimated segment of the funnel.
- Both formats titrate, so both need dose-aware billing tied to the ship event.
- Offering both is a coverage strategy as much as a preference one.
The constraint nobody prices in
Injectable GLP-1 formulations degrade outside a defined temperature range, so they can only be filled by pharmacies qualified for cold-chain shipping. Not every compounding pharmacy is.
That means your addressable state map for injectables is the intersection of pharmacy licensure and cold-chain qualification, not licensure alone. Operators routinely discover this after advertising into states they cannot reliably serve.
Oral formats, including sublingual and ODT preparations, do not carry that constraint. They can be filled by any qualified pharmacy licensed in the state.
Needle aversion is a funnel segment
A meaningful share of patients who are otherwise eligible and motivated will not self-inject. In a funnel where you have already paid for the click, an oral option converts patients an injectable-only catalog declines.
This is one of the clearest cases in telehealth where a catalog decision is directly an acquisition-efficiency decision.
What stays the same
Both formats titrate, so both require billing that fires on the ship event at the dose actually dispensed, with a provider-reviewed check-in gating the step. Both require eligibility screening inside the intake before checkout. Both are prescribed by a provider licensed in the patient's state.
The clinical selection between formats belongs to the provider and the patient. Nothing here is medical guidance.
| Injectable | Oral | |
|---|---|---|
| Cold chain required | Yes | No |
| Constrains state coverage | Yes | No |
| Needle aversion barrier | Yes | No |
| Titrates | Yes | Yes |
| Typical dosing | Per 4 weeks | Daily |
| Silent failure risk | Temperature excursion | Low |
The silent failure argument
A cold-chain excursion usually produces no visible event. The parcel arrives, the patient uses it, and the therapy simply underperforms. The patient concludes it does not work for them and cancels around month three, and the churn is attributed to the product.
Oral formats remove that failure mode entirely. For states where your cold-chain coverage is thin, that is a retention argument as well as a logistics one.
Both formats, routed on qualification
PharmaBro routes each order on the specific compound, format and state, sending temperature-sensitive orders only to cold-chain-qualified partners and oral formats to any qualified pharmacy licensed in that state.
Carrying both formats widens both your addressable states and your addressable patients, on one catalog and one workflow.
Conclusion
The oral versus injectable decision is usually discussed as patient preference and is really about coverage.
Injectables constrain you to cold-chain-qualified pharmacies and carry a silent failure mode. Orals remove both and convert the needle-averse segment. Carry both, and let routing and the provider decide per case.
Frequently asked questions
Do oral GLP-1 formats need cold chain shipping?
No. Oral, sublingual and ODT preparations do not carry the temperature constraint that injectable formulations do, which means they can be filled by any qualified pharmacy licensed in the patient's state.
Does offering an oral option increase conversion?
It converts patients who are eligible and motivated but will not self-inject, which is a meaningful segment. In a paid-acquisition funnel that is efficiency you have already bought and would otherwise decline.
Do both formats need dose-aware billing?
Yes. Both titrate, so in both cases billing should fire on the day the pharmacy ships at the dose actually dispensed, with a provider-reviewed check-in gating the dose step.
References
Dana WhitfieldDirector of Pharmacy Operations
Runs the pharmacy network and the routing layer. Has negotiated enough fulfillment agreements to have strong opinions about why launches actually slip.